Muscular Dystrophy Association Celebrates FDA Approval of Biogen’s Qalsody for…
<!-- Name:DistributionId Value:8825434 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
SOD1ALS
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
<!-- Name:DistributionId Value:8793929 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful…
12-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength, and quality of lifeTofersen also led to robust and…
Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label…
In the Phase 3 VALOR study, the primary endpoint as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) did not reach statistical significance; however,…